417 related articles for article (PubMed ID: 33177194)
21. Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.
Pegu A; Xu L; DeMouth ME; Fabozzi G; March K; Almasri CG; Cully MD; Wang K; Yang ES; Dias J; Fennessey CM; Hataye J; Wei RR; Rao E; Casazza JP; Promsote W; Asokan M; McKee K; Schmidt SD; Chen X; Liu C; Shi W; Geng H; Foulds KE; Kao SF; Noe A; Li H; Shaw GM; Zhou T; Petrovas C; Todd JP; Keele BF; Lifson JD; Doria-Rose NA; Koup RA; Yang ZY; Nabel GJ; Mascola JR
Cell Rep; 2022 Jan; 38(1):110199. PubMed ID: 34986348
[TBL] [Abstract][Full Text] [Related]
22. Long-Term and Low-Level Envelope C2V3 Stimulation by Highly Diverse Virus Isolates Leads to Frequent Development of Broad and Elite Antibody Neutralization in HIV-1-Infected Individuals.
Martin F; Marcelino JM; Palladino C; Bártolo I; Tracana S; Moranguinho I; Gonçalves P; Mateus R; Calado R; Borrego P; Leitner T; Clemente S; Taveira N
Microbiol Spectr; 2022 Dec; 10(6):e0163422. PubMed ID: 36445130
[TBL] [Abstract][Full Text] [Related]
23. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers.
Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD
Front Immunol; 2021; 12():670561. PubMed ID: 35003053
[TBL] [Abstract][Full Text] [Related]
24. Targeting the HIV-1 Spike and Coreceptor with Bi- and Trispecific Antibodies for Single-Component Broad Inhibition of Entry.
Khan SN; Sok D; Tran K; Movsesyan A; Dubrovskaya V; Burton DR; Wyatt RT
J Virol; 2018 Sep; 92(18):. PubMed ID: 29976677
[TBL] [Abstract][Full Text] [Related]
25. Simian-Human Immunodeficiency Virus SHIV.CH505 Infection of Rhesus Macaques Results in Persistent Viral Replication and Induces Intestinal Immunopathology.
Bar KJ; Coronado E; Hensley-McBain T; O'Connor MA; Osborn JM; Miller C; Gott TM; Wangari S; Iwayama N; Ahrens CY; Smedley J; Moats C; Lynch RM; Haddad EK; Haigwood NL; Fuller DH; Shaw GM; Klatt NR; Manuzak JA
J Virol; 2019 Sep; 93(18):. PubMed ID: 31217249
[TBL] [Abstract][Full Text] [Related]
26. Development of Antibodies with Broad Neutralization Specificities against HIV-1 after Long Term SHIV Infection in Macaques.
Gao N; Gai Y; Meng L; Wang C; Zhang X; Wang W; Qin C; Yu X; Gao F
Viruses; 2020 Jan; 12(2):. PubMed ID: 32023860
[TBL] [Abstract][Full Text] [Related]
27. Susceptibility to Neutralization by Broadly Neutralizing Antibodies Generally Correlates with Infected Cell Binding for a Panel of Clade B HIV Reactivated from Latent Reservoirs.
Ren Y; Korom M; Truong R; Chan D; Huang SH; Kovacs CC; Benko E; Safrit JT; Lee J; Garbán H; Apps R; Goldstein H; Lynch RM; Jones RB
J Virol; 2018 Dec; 92(23):. PubMed ID: 30209173
[TBL] [Abstract][Full Text] [Related]
28. Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C Infection.
Wagh K; Bhattacharya T; Williamson C; Robles A; Bayne M; Garrity J; Rist M; Rademeyer C; Yoon H; Lapedes A; Gao H; Greene K; Louder MK; Kong R; Karim SA; Burton DR; Barouch DH; Nussenzweig MC; Mascola JR; Morris L; Montefiori DC; Korber B; Seaman MS
PLoS Pathog; 2016 Mar; 12(3):e1005520. PubMed ID: 27028935
[TBL] [Abstract][Full Text] [Related]
29. Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies.
Cheeseman HM; Olejniczak NJ; Rogers PM; Evans AB; King DFL; Ziprin P; Liao HX; Haynes BF; Shattock RJ
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795431
[TBL] [Abstract][Full Text] [Related]
30. Functional Stability of HIV-1 Envelope Trimer Affects Accessibility to Broadly Neutralizing Antibodies at Its Apex.
Gift SK; Leaman DP; Zhang L; Kim AS; Zwick MB
J Virol; 2017 Dec; 91(24):. PubMed ID: 28978711
[TBL] [Abstract][Full Text] [Related]
31. Reduced Potency and Incomplete Neutralization of Broadly Neutralizing Antibodies against Cell-to-Cell Transmission of HIV-1 with Transmitted Founder Envs.
Li H; Zony C; Chen P; Chen BK
J Virol; 2017 May; 91(9):. PubMed ID: 28148796
[TBL] [Abstract][Full Text] [Related]
32. Potential of conventional & bispecific broadly neutralizing antibodies for prevention of HIV-1 subtype A, C & D infections.
Wagh K; Seaman MS; Zingg M; Fitzsimons T; Barouch DH; Burton DR; Connors M; Ho DD; Mascola JR; Nussenzweig MC; Ravetch J; Gautam R; Martin MA; Montefiori DC; Korber B
PLoS Pathog; 2018 Mar; 14(3):e1006860. PubMed ID: 29505593
[TBL] [Abstract][Full Text] [Related]
33. Comparison of Antibody-Dependent Cell-Mediated Cytotoxicity and Virus Neutralization by HIV-1 Env-Specific Monoclonal Antibodies.
von Bredow B; Arias JF; Heyer LN; Moldt B; Le K; Robinson JE; Zolla-Pazner S; Burton DR; Evans DT
J Virol; 2016 Jul; 90(13):6127-6139. PubMed ID: 27122574
[TBL] [Abstract][Full Text] [Related]
34. Characterizing the Relationship Between Neutralization Sensitivity and
Wilson A; Shakhtour L; Ward A; Ren Y; Recarey M; Stevenson E; Korom M; Kovacs C; Benko E; Jones RB; Lynch RM
Front Immunol; 2021; 12():710327. PubMed ID: 34603284
[TBL] [Abstract][Full Text] [Related]
35. Neutralization Synergy between HIV-1 Attachment Inhibitor Fostemsavir and Anti-CD4 Binding Site Broadly Neutralizing Antibodies against HIV.
Zhang Y; Chapman JH; Ulcay A; Sutton RE
J Virol; 2019 Feb; 93(4):. PubMed ID: 30518644
[TBL] [Abstract][Full Text] [Related]
36. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques.
Santra S; Tomaras GD; Warrier R; Nicely NI; Liao HX; Pollara J; Liu P; Alam SM; Zhang R; Cocklin SL; Shen X; Duffy R; Xia SM; Schutte RJ; Pemble Iv CW; Dennison SM; Li H; Chao A; Vidnovic K; Evans A; Klein K; Kumar A; Robinson J; Landucci G; Forthal DN; Montefiori DC; Kaewkungwal J; Nitayaphan S; Pitisuttithum P; Rerks-Ngarm S; Robb ML; Michael NL; Kim JH; Soderberg KA; Giorgi EE; Blair L; Korber BT; Moog C; Shattock RJ; Letvin NL; Schmitz JE; Moody MA; Gao F; Ferrari G; Shaw GM; Haynes BF
PLoS Pathog; 2015 Aug; 11(8):e1005042. PubMed ID: 26237403
[TBL] [Abstract][Full Text] [Related]
37. Induction of antibodies in guinea pigs and rhesus monkeys against the human immunodeficiency virus type 1 envelope: neutralization of nonpathogenic and pathogenic primary isolate simian/human immunodeficiency virus strains.
Liao HX; Etemad-Moghadam B; Montefiori DC; Sun Y; Sodroski J; Scearce RM; Doms RW; Thomasch JR; Robinson S; Letvin NL; Haynes BF
J Virol; 2000 Jan; 74(1):254-63. PubMed ID: 10590113
[TBL] [Abstract][Full Text] [Related]
38. Broadly Neutralizing Antibodies for HIV-1 Prevention.
Walsh SR; Seaman MS
Front Immunol; 2021; 12():712122. PubMed ID: 34354713
[TBL] [Abstract][Full Text] [Related]
39. HIV Broadly Neutralizing Antibodies Expressed as IgG3 Preserve Neutralization Potency and Show Improved Fc Effector Function.
Richardson SI; Ayres F; Manamela NP; Oosthuysen B; Makhado Z; Lambson BE; Morris L; Moore PL
Front Immunol; 2021; 12():733958. PubMed ID: 34566999
[TBL] [Abstract][Full Text] [Related]
40. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.
Ko SY; Pegu A; Rudicell RS; Yang ZY; Joyce MG; Chen X; Wang K; Bao S; Kraemer TD; Rath T; Zeng M; Schmidt SD; Todd JP; Penzak SR; Saunders KO; Nason MC; Haase AT; Rao SS; Blumberg RS; Mascola JR; Nabel GJ
Nature; 2014 Oct; 514(7524):642-5. PubMed ID: 25119033
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
